Expressing concern over poor detection of spurious drug network in the country, Sinha said, "According to the statistics of the year 2011-12 (upto March 2012) of Ministry of Health and Family Welfare, out of 48,082 drugs tested across the country, 133 turned out to be fake, which translates to roughly 0.27 per cent."
He said prosecution was launched only in 0.43 per cent of these 133 cases and only 0.23 per cent of accused who were found involved in the manufacture of these fake drugs were arrested.
"...Counterfeiting cases that are detected and investigated are not prosecuted, perhaps due to certain weaknesses in investigation. Needless to say that the investigating capability of officers is required to be beefed up," Sinha said.
The CBI Chief said low detection rate could be due to lack of an efficient intelligence collection apparatus or awareness among the stake holders.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
